WO1997022376A1 - Nebuliseur - Google Patents

Nebuliseur Download PDF

Info

Publication number
WO1997022376A1
WO1997022376A1 PCT/GB1996/003201 GB9603201W WO9722376A1 WO 1997022376 A1 WO1997022376 A1 WO 1997022376A1 GB 9603201 W GB9603201 W GB 9603201W WO 9722376 A1 WO9722376 A1 WO 9722376A1
Authority
WO
WIPO (PCT)
Prior art keywords
gas
nebuliser
supply
liquid
nebulizer
Prior art date
Application number
PCT/GB1996/003201
Other languages
English (en)
Inventor
Surinderjit Kumar Jassell
Original Assignee
Intersurgical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intersurgical Limited filed Critical Intersurgical Limited
Priority to AU12017/97A priority Critical patent/AU1201797A/en
Priority to EP96943222A priority patent/EP0959925A1/fr
Publication of WO1997022376A1 publication Critical patent/WO1997022376A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles

Definitions

  • Nebulizers are used to produce a liquid m fine droplet form in a gas flow, typically a liquid in the form of medication which is to be entrained in an air or oxygen gas flow and which is then breathed by a patient whereby the medication is supplied to the patient through the lungs.
  • Nebulizers are becoming widely used in hospitals and other medical situations. Such as
  • nebulizers have particular application in the delivery of drugs for the treatment of lung diseases.
  • ⁇ e drug may be given as an inhaled drug aerosol, and this has many advantages over drugs which are taken systemically. It has become apparent that the size of the droplets plays an important role in how the drug is received by
  • European Patent specification EP-A-573457 demonstrates a typical nebulizer and there is included in that specification details of the effect of droplet size on the delivery of the medicauon.
  • the present invention provides a nebulizer comprising a pressure gas inlet, means for passing liquid medication to nebulising means associated with said pressure gas inlet
  • the nebulizer may include a reservoir for said liquid medication, and the control means may include means to vary the size of the supply means so as to vary the amount of further gas passing through said further gas supply means.
  • the control means may be in the form of a variable aperture, which may be provided by an aperture with a plate with a cooperating aperture therein, the plate being moveable.
  • the control means may also include a one way valve.
  • An advantage of the arrangement of the invention is that the quantity and relative constitution of the nebulized mixture may be changed by varying the control means to control the supply of further gas.
  • Figure 1 is a axial section through a nebulizer according to the invention
  • Figure 2 is a perspective view of the nebulizer of Figure 1 from the right
  • Figure 3 is a view similar to Figure 2 of the nebulizer with the air controller in a second position
  • Figure 4 is a view corresponding to Figures 2 and 3 of the nebulizer, with the air controller missing, showing the inlet air valve,
  • Figure 5 is a pan view showing one line of ratchet teeth mounted on the nebul ⁇ zer( with air controller missing), and,
  • Figure 6 is rear view of the air controller showing the teeth to engage the ratchet shown in Figure 5.
  • FIG. 1 there is shown an axial section through a nebulizer (10).
  • the section shown in Figure 1 comp ⁇ ses, on the left hand side of the Figure 1 , a first ve ⁇ ical section, and on the ⁇ ght hand side of the Figure a second ve ⁇ icaJ section at ⁇ ght angles to the first
  • the nebulizer is manufactured of ⁇ gid moulded plastics mate ⁇ al.
  • the nebulizer compnses a base section (1 1) which includes an inlet tube ( 12) for connection to a flexible plastic tube supplying pressurized gas, such as oxygen or air.
  • the inlet tube (12) is sunounded by a threaded collar (13).
  • Forming pan of the base section ( 1 1) but separately moulded is a second moulding ( 16) which includes; (a) a cylindncal stem portion (17) which closely sunounds the
  • a jet mounting portion which includes a jet (20A) which overlies a jet (20B) in the upper end of the inlet (12); and (c) a collar portion (21 ) which comprises a frusto conical plate (22) surrounding the jet mounting po ⁇ ion (19) and
  • the inner generally cylindrical surface (21A) of the collar portion (21) immediately sunounding the jet comprises a frusto-conical surface of the apex of which is below the collar and is at an angle of about 8° to the axis.
  • the jet (20A) and jet (20B) combine to provide a gas/liquid mixing jet (20).
  • the collar (32) communicates via pathways (33, 34) with an ambient air inlet (36) mounted on the side of the outer housing (27).
  • the ambient air inlet (36) is closed by a one way valve (37) in the form of a flexible diaphragm (38) of plastic, neoprene, or rubber mounted centrally at (39) and which engages with a rim (41) sunounding the ambient air inlet (36).
  • the ambient air inlet (36) includes a circular opening (42) defined by the rim (41) and an adjustable air controller (43) is provided
  • the adjustable air controller (43) comprises a plate like member (44) mounted to slide vertically with respect to the housing (27) and includes an aperture (46) which, as the plate (44) slides, may selectively align with the circular opening (42).
  • Figure 2 shows the general arrangement of the plate (44), in a first position in which the air inlet (36) is closed and
  • Figure 3 shows the plate (44) in a second position in which the air inlet (36) is open.
  • Figures 4 shows the nebulizer with the plate (44) removed thereby showing more clearly the circular opening (42).
  • each side of the opening (42) there is moulded into the outer housing (27) a pair of vertically extending edges (47, 48) which each include a respective ratchet track (51 , 52) which are illustrated in more detail in Figure 5.
  • the plate (44) Spaced from and aligned into the conesponding vertically extending edges (47, 48), the plate (44) has ve ⁇ ically extending faces (53, 54) illustrated in Figure 6.
  • Each face (53.54) includes a respective upper and lower tooth (56, 57) for engaging with the respective adjacent ratchet track (51 , 52).
  • inlet tube (12) is connected by means of a flexible plastic pipe to a suitable pressurised supply of air or oxygen and the outlet (28) is connected, usually by tubes, to a patient.
  • the plate (44) is slid up or down so that the aperture (46) coincides with the circular opening (42) to a desired extent and is held in the desired position by engagement of the teeth (56,57) with their respective ratchet tracks (51 ,52).
  • the liquid medication passes from top reservoir (14) up the capillary path (18) and as the pressurised air or oxygen passes through the jet (20B), mixes with the liquid passing
  • air is drawn into the ambient air inlet (36) via the one way valve (37), through the pathways (33,34) to join and mix with the nebulized stream assisting in the breaking up of the gas liquid stream into finer droplets and in increasing the aerosol output being delivered through the outlet (28).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nozzles (AREA)

Abstract

Ce nébuliseur comporte un orifice d'entrée (12) de gaz sous pression, un moyen (18) permettant de faire passer un liquide thérapeutique vers un dispositif (20) de nébulisation associé à l'orifice d'entrée de gaz sous pression pour mélanger le gaz provenant de l'orifice d'entrée de gaz sous pression avec ledit liquide thérapeutique, afin de produire un mélange nébulisé de liquide et de gaz, un moyen (36) destiné à fournir du gaz supplémentaire, à mélanger avec ledit mélange nébulisé, ledit moyen d'apport de gaz supplémentaire comportant un dispositif de régulation (43) destiné à réguler l'apport en gaz supplémentaire.
PCT/GB1996/003201 1995-12-20 1996-12-20 Nebuliseur WO1997022376A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU12017/97A AU1201797A (en) 1995-12-20 1996-12-20 Nebulizer
EP96943222A EP0959925A1 (fr) 1995-12-20 1996-12-20 Nebuliseur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9526100.4 1995-12-20
GB9526100A GB9526100D0 (en) 1995-12-20 1995-12-20 Nebulizer

Publications (1)

Publication Number Publication Date
WO1997022376A1 true WO1997022376A1 (fr) 1997-06-26

Family

ID=10785782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003201 WO1997022376A1 (fr) 1995-12-20 1996-12-20 Nebuliseur

Country Status (4)

Country Link
EP (1) EP0959925A1 (fr)
AU (1) AU1201797A (fr)
GB (1) GB9526100D0 (fr)
WO (1) WO1997022376A1 (fr)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2005097175A2 (fr) 2004-03-31 2005-10-20 Centocor, Inc. Corps mimetiques glp-1 humains, compositions, procedes et utilisations
WO2008021237A1 (fr) 2006-08-10 2008-02-21 Arubor Corporation Thérapie locale de troubles inflammatoires des voies aériennes inférieures avec des inhibiteurs de cytokine proinflammatoire
EP2090657A2 (fr) 2000-08-07 2009-08-19 Centocor Ortho Biotech Inc. Anticorps anti-IL-12, compositions, procédés et utilisations
EP2123675A2 (fr) 2003-09-30 2009-11-25 Centocor Ortho Biotech Inc. Mimétiques de l'EPO humaine à région centrale à charnière, compositions, procédés et utilisations
EP2159230A1 (fr) 2000-08-07 2010-03-03 Centocor Ortho Biotech Inc. Anticorps anti-TNF, compositions, procédés et utilisations
WO2010051274A2 (fr) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Compositions d'échafaudage à base de domaines de la fibronectine de type iii, procédés et utilisations
US7718176B2 (en) 2004-09-03 2010-05-18 Cna Development Llc Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2010093627A2 (fr) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
US7833531B2 (en) 2006-12-21 2010-11-16 Centocor, Inc. Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
EP2253646A1 (fr) 2000-08-07 2010-11-24 Centocor Ortho Biotech Inc. Anticorps anti intégrines doubles et compositions et conjugés les contenant
EP2308888A1 (fr) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anticorps anti-IL-6, compositions, méthodes et utilisations associées
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
EP2452694A1 (fr) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anticorps anti-IL-23, compositions, procédés et utilisations
EP2548577A1 (fr) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Anticorps humains anti-IL-23, compositions, procédés et utilisations
WO2014106459A2 (fr) 2013-01-07 2014-07-10 Superlab Far East Limited Procédé de traitement d'une tumeur en utilisant un interféron recombinant avec une configuration spatiale modifiée
WO2014144763A2 (fr) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center Anticorps anti-gd2 à haute affinité
EP2842968A1 (fr) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anticorps anti-IL-6, compositions, procédés et utilisations
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
WO2018014039A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs d'antigènes chimériques (cars) spécifiques pour muc1 et leurs procédés d'utilisation
WO2018014038A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs antigéniques chimériques et leurs procédés d'utilisation
EP3323830A1 (fr) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
WO2018140026A1 (fr) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Molécules bispécifiques de liaison à her2 et cd3
WO2019126574A1 (fr) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions de vcar et méthodes d'utilisation
WO2019215701A1 (fr) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Méthodes de traitement de la dépression à l'aide d'anticorps il-23
WO2020148651A1 (fr) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile
WO2020152544A1 (fr) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
WO2020183269A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
WO2020183271A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020183270A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020245676A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
WO2020245677A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
WO2021211628A1 (fr) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions et méthodes destinées à être utilisées dans le traitement du cancer
WO2021214588A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections à coronavirus
WO2021214587A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections virales
WO2022026943A2 (fr) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Peptides de fusion de la neuropiline et de l'enzyme de conversion de l'angiotensine 2 pour le traitement d'infections virales
WO2023279115A1 (fr) 2021-07-02 2023-01-05 Henry Ford Health System COMPOSITIONS COMPRENANT DE L'ENDOSIDINE 2 POUR RÉDUIRE UNE INFECTION À SARS-CoV-2
WO2023281462A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
WO2023281463A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
EP4190817A1 (fr) 2015-03-17 2023-06-07 Memorial Sloan Kettering Cancer Center Anticorps anti-muc16 et leurs utilisations
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001731A1 (fr) * 1984-09-18 1986-03-27 Vortran Corporation Vaporisateur servant a divers usages
US4819629A (en) * 1986-10-28 1989-04-11 Siemens Aktiengesellschaft Method and apparatus for delivering aerosol to the airways and/or lungs of a patient
US5054477A (en) * 1986-09-22 1991-10-08 Omron Tateisi Electronics Co. Nebulizer
US5301662A (en) * 1991-09-25 1994-04-12 Cimco, Inc. Nebulizer with high oxygen content and high total flow rate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001731A1 (fr) * 1984-09-18 1986-03-27 Vortran Corporation Vaporisateur servant a divers usages
US5054477A (en) * 1986-09-22 1991-10-08 Omron Tateisi Electronics Co. Nebulizer
US4819629A (en) * 1986-10-28 1989-04-11 Siemens Aktiengesellschaft Method and apparatus for delivering aerosol to the airways and/or lungs of a patient
US5301662A (en) * 1991-09-25 1994-04-12 Cimco, Inc. Nebulizer with high oxygen content and high total flow rate

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3118318A1 (fr) 2000-08-07 2017-01-18 Janssen Biotech, Inc. Anticorps anti-tnf, compositions, procédés et utilisations
EP3597752A1 (fr) 2000-08-07 2020-01-22 Janssen Biotech, Inc. Anticorps anti-il-12, compositions, procédés et utilisations
EP2330129A2 (fr) 2000-08-07 2011-06-08 Centocor Ortho Biotech Inc. Anticorps anti-TNF, compositions, procédés et utilisations
EP2090657A2 (fr) 2000-08-07 2009-08-19 Centocor Ortho Biotech Inc. Anticorps anti-IL-12, compositions, procédés et utilisations
EP2159230A1 (fr) 2000-08-07 2010-03-03 Centocor Ortho Biotech Inc. Anticorps anti-TNF, compositions, procédés et utilisations
EP2305817A2 (fr) 2000-08-07 2011-04-06 Centocor Ortho Biotech Inc. Anticorps anti-IL-12, compositions, procédés et utilisations
EP2253646A1 (fr) 2000-08-07 2010-11-24 Centocor Ortho Biotech Inc. Anticorps anti intégrines doubles et compositions et conjugés les contenant
EP2308888A1 (fr) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anticorps anti-IL-6, compositions, méthodes et utilisations associées
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
EP2123675A2 (fr) 2003-09-30 2009-11-25 Centocor Ortho Biotech Inc. Mimétiques de l'EPO humaine à région centrale à charnière, compositions, procédés et utilisations
WO2005097175A2 (fr) 2004-03-31 2005-10-20 Centocor, Inc. Corps mimetiques glp-1 humains, compositions, procedes et utilisations
US7718176B2 (en) 2004-09-03 2010-05-18 Cna Development Llc Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
EP2842968A1 (fr) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anticorps anti-IL-6, compositions, procédés et utilisations
EP3501537A1 (fr) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anticorps anti-il23, compositions, procédés et utilisations
EP2452694A1 (fr) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anticorps anti-IL-23, compositions, procédés et utilisations
EP3760230A1 (fr) 2005-12-29 2021-01-06 Janssen Biotech, Inc. Anticorps humains anti-il-23, compositions, procédés et utilisations
EP3219328A1 (fr) 2005-12-29 2017-09-20 Janssen Biotech, Inc. Compositions, procédés et utilisations d'anticorps humains anti-il-23
EP2548577A1 (fr) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Anticorps humains anti-IL-23, compositions, procédés et utilisations
US11718853B2 (en) 2006-08-10 2023-08-08 Onspira Therapeutics, Inc. Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
EP3669878A1 (fr) 2006-08-10 2020-06-24 Roy C. Levitt Thérapie localisée des troubles inflammatoires des voies respiratoires inférieures avec des inhibiteurs de cytokines inflammatoires
WO2008021237A1 (fr) 2006-08-10 2008-02-21 Arubor Corporation Thérapie locale de troubles inflammatoires des voies aériennes inférieures avec des inhibiteurs de cytokine proinflammatoire
US7833531B2 (en) 2006-12-21 2010-11-16 Centocor, Inc. Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
EP3128048A1 (fr) 2008-10-31 2017-02-08 Janssen Biotech, Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
WO2010051274A2 (fr) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Compositions d'échafaudage à base de domaines de la fibronectine de type iii, procédés et utilisations
WO2010093627A2 (fr) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
EP3323830A1 (fr) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
EP4269563A2 (fr) 2010-06-19 2023-11-01 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
WO2014106459A2 (fr) 2013-01-07 2014-07-10 Superlab Far East Limited Procédé de traitement d'une tumeur en utilisant un interféron recombinant avec une configuration spatiale modifiée
EP3895725A2 (fr) 2013-01-07 2021-10-20 Superlab Far East Limited Procédé de traitement de tumeurs au moyen d'interféron recombinant à configuration spatiale modifiée
WO2014144763A2 (fr) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center Anticorps anti-gd2 à haute affinité
EP4190817A1 (fr) 2015-03-17 2023-06-07 Memorial Sloan Kettering Cancer Center Anticorps anti-muc16 et leurs utilisations
WO2018014038A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs antigéniques chimériques et leurs procédés d'utilisation
WO2018014039A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs d'antigènes chimériques (cars) spécifiques pour muc1 et leurs procédés d'utilisation
WO2018140026A1 (fr) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Molécules bispécifiques de liaison à her2 et cd3
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2019126574A1 (fr) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions de vcar et méthodes d'utilisation
WO2019215701A1 (fr) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Méthodes de traitement de la dépression à l'aide d'anticorps il-23
WO2020148651A1 (fr) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile
WO2020152544A1 (fr) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
WO2020183271A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020183270A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020183269A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2020245677A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
WO2020245676A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
WO2021211628A1 (fr) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions et méthodes destinées à être utilisées dans le traitement du cancer
WO2021214588A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections à coronavirus
WO2021214587A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections virales
WO2022026943A2 (fr) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Peptides de fusion de la neuropiline et de l'enzyme de conversion de l'angiotensine 2 pour le traitement d'infections virales
WO2023279115A1 (fr) 2021-07-02 2023-01-05 Henry Ford Health System COMPOSITIONS COMPRENANT DE L'ENDOSIDINE 2 POUR RÉDUIRE UNE INFECTION À SARS-CoV-2
WO2023281463A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
WO2023281462A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf

Also Published As

Publication number Publication date
AU1201797A (en) 1997-07-14
GB9526100D0 (en) 1996-02-21
EP0959925A1 (fr) 1999-12-01

Similar Documents

Publication Publication Date Title
EP0959925A1 (fr) Nebuliseur
US7726306B2 (en) Intra-oral nebulizer with rainfall chamber
EP0880373B1 (fr) Dispositif de nebulisation
AU712312B2 (en) Breathing circuit apparatus for a nebulizer
US9907918B2 (en) Nebulizer apparatus and method
US7712466B2 (en) Intra-oral nebulizer
EP0653946B1 (fr) Nebuliseur a faible debit
CA1130160A (fr) Atomiseur a debit reglable
US7493898B2 (en) Inhalation apparatus
DE19726110A1 (de) Ultraschallvernebler für Beatmungssysteme
US8439030B2 (en) Nebulizer device
AU2004202959B2 (en) Nebulizer Apparatus and Method
AU771684B2 (en) Nebulizer apparatus and method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996943222

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97522603

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996943222

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996943222

Country of ref document: EP